| scholarly article | Q13442814 |
| P356 | DOI | 10.2215/CJN.00870207 |
| P698 | PubMed publication ID | 17702732 |
| P50 | author | Björn Anderstam | Q114338533 |
| Mengli Tong | Q114338556 | ||
| Anders Alvestrand | Q114338557 | ||
| Juan J Carrero | Q37828646 | ||
| Peter Stenvinkel | Q37828656 | ||
| Abdul Rashid Qureshi | Q41896648 | ||
| Peter Barany | Q51756080 | ||
| Bengt Lindholm | Q63372914 | ||
| Olof Heimbürger | Q65927824 | ||
| P2093 | author name string | Jonas Axelsson | |
| Mohamed E Suliman | |||
| P433 | issue | 5 | |
| P921 | main subject | patient | Q181600 |
| cardiovascular disease | Q389735 | ||
| chronic renal insufficiency | Q736715 | ||
| P304 | page(s) | 889-897 | |
| P577 | publication date | 2007-08-16 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality | |
| P478 | volume | 2 |
| Q93186355 | Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo |
| Q41839109 | Annual decline in pentraxin 3 is a risk of vascular access troubles in hemodialysis patients |
| Q36533057 | Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly |
| Q36206630 | Association between serum neopterin and inflammatory activation in chronic kidney disease |
| Q37041355 | Association of Serum Pentraxin-3 and High-Sensitivity C-Reactive Protein with the Extent of Coronary Stenosis in Patients Undergoing Coronary Angiography |
| Q35624204 | Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR >60 mL/min/1.73 m(2): the Multi-Ethnic Study of Atherosclerosis (MESA) |
| Q37141153 | Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study |
| Q34150807 | Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study |
| Q36200128 | Biochemical analysis of pentraxin 3 and fibrinogen levels in experimental periodontitis model |
| Q47216784 | Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update |
| Q38084920 | Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease |
| Q37893446 | Biomarkers in chronic kidney disease: a review |
| Q26799505 | Biomarkers of Renal Disease and Progression in Patients with Diabetes |
| Q33571343 | CRP polymorphisms and progression of chronic kidney disease in African Americans |
| Q57025025 | Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease |
| Q51629721 | Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3. |
| Q33944773 | Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation |
| Q40865321 | Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function |
| Q46071688 | Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations |
| Q38683930 | Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima-media thickness. |
| Q37123175 | Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria |
| Q34713240 | Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. |
| Q33345061 | Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? |
| Q34747124 | Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation |
| Q37370584 | Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population |
| Q40161972 | Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation |
| Q36463833 | Host-protective effect of circulating pentraxin 3 (PTX3) and complex formation with neutrophil extracellular traps. |
| Q41199330 | Impact of Thermal Stress on Kidney-Specific Gene Expression in Farmed Regional and Imported Rainbow Trout. |
| Q64074449 | Inevitable isolation and the change of stress markers in hemodialysis patients during the 2015 MERS-CoV outbreak in Korea |
| Q46237239 | Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss |
| Q37629231 | Interesting Correlation Between the Circulating Pentraxin 3 and Cardiac Rehabilitation Program Outcomes in Coronary Artery Bypass Grafting Patients |
| Q35664554 | Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease |
| Q30245541 | Investigating Prevalence and Pattern of Long-term Cardiovascular Disorders in Sulphur Mustard-exposed Victims and Determining Proper Biomarkers for Early Defining, Monitoring and Analysis of Patients' Feedback on Therapy |
| Q57060381 | Large uremic toxins: an unsolved problem in end-stage kidney disease |
| Q86904001 | Left ventricular diastolic dysfunction by tissue Doppler echocardiography in pediatric chronic kidney disease |
| Q46749995 | Levels of pentraxin-3 in gingival crevicular fluid and plasma in periodontal health and disease. |
| Q91970155 | Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality |
| Q36736700 | Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease |
| Q50143105 | PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer |
| Q31057428 | Pentraxin 3 (PTX3) expression in allergic asthmatic airways: role in airway smooth muscle migration and chemokine production |
| Q51076609 | Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus. |
| Q39252622 | Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease. |
| Q64105040 | Pentraxin 3 in Cardiovascular Disease |
| Q35755280 | Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease |
| Q38901060 | Pentraxin-3 Attenuates Renal Damage in Diabetic Nephropathy by Promoting M2 Macrophage Differentiation |
| Q36164346 | Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts. |
| Q34683473 | Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. |
| Q38991073 | Pentraxins in the activation and regulation of innate immunity |
| Q38050188 | Periodontal diseases and systemic inflammation |
| Q43142703 | Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients |
| Q45415175 | Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease |
| Q58104494 | Plasma levels of endothelial cell-specific molecule-1 and pentraxin-3 in idiopathic sudden sensorineural hearing loss |
| Q44456570 | Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients |
| Q48324307 | Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea |
| Q35024794 | Protein-energy wasting and mortality in chronic kidney disease |
| Q38341211 | Proteomic biomarkers in kidney disease: issues in development and implementation |
| Q53402095 | Quality of life on hemodialysis and inflammation: a descriptive analysis. |
| Q35133148 | Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis |
| Q43181277 | Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome |
| Q36551416 | Relationship between Plasma Pentraxin-3, Neutrophil-to-Lymphocyte Ratio, and Atherosclerosis in Renal Transplant Patients. |
| Q52761490 | Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study. |
| Q51345186 | Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes. |
| Q84264492 | Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentraxin-3 levels: a case-control study |
| Q34751855 | Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes |
| Q37530584 | Sputum pentraxin 3 as a candidate to assess airway inflammation and remodeling in childhood asthma. |
| Q64118817 | The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis |
| Q45377428 | The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients |
| Q89172353 | The effect of periodontal disease treatment in patients with continuous ambulatory peritoneal dialysis |
| Q39230390 | The immunology of atherosclerosis |
| Q37851153 | The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling |
| Q38092832 | The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules |
| Q50971105 | The long pentraxin-3 is a useful marker for diagnosis of ovarian torsion: An experimental rat model. |
| Q47848978 | The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients |
| Q38546860 | Therapeutics targeting persistent inflammation in chronic kidney disease |
| Q35227705 | Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients |
| Q34724967 | Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease |
Search more.